Syndax Pharmaceuticals Inc

By person

19 insiders · 130 transactions

15.5×

Michael A. Metzger holds 15.5 times base salary in stock. $11.75M of shares against $754.30K in salary for 2025.

Salary from the company's own proxy. The shares are what Michael A. Metzger last reported holding, valued at $24.24, the price Common Stock was last bought or sold at on the open market here, on 8 Jul 2026.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Morrison Briggs

Director

$311.64K (4)

$26.01M (25) scheduled

−$25.70M

34,836

0.0390%

$844.43K

+1,207%

Metzger Michael A

Chief Executive Officer

—

$15.40M (34) scheduled

−$15.40M

484,843

0.5430%

$11.75M

—

Ordentlich Peter

Chief Scientific Officer

—

$2.81M (14) scheduled

−$2.81M

0.0000%

$0.00

−100.0%

Podlesak Dennis

Director

$197.08K (1)

$2.77M (6) scheduled

−$2.58M

239,763

0.2685%

$5.81M

—

Legault Pierre

Director

—

$2.55M (7) scheduled

−$2.55M

114,000

0.1277%

$2.76M

—

Meury William

Director

—

$1.70M (3) scheduled

−$1.70M

90,000

0.1008%

$2.18M

—

Botwood Nicholas A.J.

Head of R&D, CMO

$105.83K (1)

$1.18M (2) scheduled

−$1.08M

60,885

0.0682%

$1.48M

+6,780%

Egros Fabrice

Director

—

$1.00M (7) scheduled

−$1.00M

32,000

0.0358%

$775.69K

—

Katkin Keith

Director

$91.12K (1)

$877.19K (8) scheduled

−$786.07K

124,000

0.1389%

$3.01M

—

Goldan Keith A.

Chief Financial Officer

$25.04K (2)

$220.45K (6)

−$195.42K

139,252

0.1559%

$3.38M

—

Gallagher Neil

President, Head of R&D

—

$71.60K (1)

−$71.60K

85,095

0.0953%

$2.06M

—

Huber Martin H. Jr.

Director

$44.95K (1)

—

+$44.95K

103,000

0.1153%

$2.50M

—

Nolte Alexander

Chief Accounting Officer

—

$16.12K (1)

−$16.12K

0.0000%

$0.00

—

Meyers Michael L.

SVP, Chief Medical Officer

$14.12K (4)

—

+$14.12K

23,280

0.0261%

$564.31K

+955.3%

ROYSTON IVOR

Director

—

625,545

0.7005%

$15.16M

−16.7%

Jarrett Jennifer

Director

—

114,000

0.1277%

$2.76M

—

BVF PARTNERS L P/IL entity

10% owner

—

85,038

0.0952%

$2.06M

−95.9%

Rizo Aleksandra

Director

—

49,000

0.0549%

$1.19M

—

Shea Richard P

Chief Financial Officer

—

7,121

0.0080%

$172.61K

+320.4%

Individual transactions

Insider

Date

Role

Action

Price

Amount

Metzger Michael A

1 Jun 2026

Chief Executive Officer

Sell

6,847

$18.99

$130.02K

Goldan Keith A.

1 Jun 2026

Chief Financial Officer

Sell

1,177

$18.99

$22.35K

Goldan Keith A.

9 Feb 2026

Chief Financial Officer

Sell

3,410

$21.03

$71.71K

Metzger Michael A

9 Feb 2026

Chief Executive Officer

Sell

17,159

$21.03

$360.82K

Goldan Keith A.

6 Feb 2026

Chief Financial Officer

Sell

2,082

$20.62

$42.93K

Metzger Michael A

6 Feb 2026

Chief Executive Officer

Sell

7,412

$20.62

$152.84K

Metzger Michael A

16 Jul 2025

Chief Executive Officer

Sell

7,534

$9.29

$69.95K

Goldan Keith A.

16 Jul 2025

Chief Financial Officer

Sell

1,296

$9.29

$12.03K

Gallagher Neil

10 Feb 2025

President, Head of R&D

Sell

4,618

$15.50

$71.60K

Metzger Michael A

10 Feb 2025

Chief Executive Officer

Sell

13,288

$15.50

$206.02K

Goldan Keith A.

10 Feb 2025

Chief Financial Officer

Sell

3,777

$15.50

$58.56K

Goldan Keith A.

13 Jun 2023

Chief Financial Officer

Sell

577

$22.31

$12.87K

Ordentlich Peter

1 Feb 2023

Chief Scientific Officer

Sell

$28.43

$1.96K

Nolte Alexander

1 Feb 2022

Chief Accounting Officer

Sell

968

$16.65

$16.12K

Ordentlich Peter

1 Feb 2022

Chief Scientific Officer

Sell

1,412

$16.65

$23.51K

Show all 130 transactions →

Syndax Pharmaceuticals Inc

By person

Individual transactions

What was left out